Agilent Technologies, Inc. (A) Given Hold Rating at Cowen and Company
Agilent Technologies, Inc. (NYSE:A)‘s stock had its “hold” rating reissued by investment analysts at Cowen and Company in a research note issued on Wednesday. They currently have a $70.00 target price on the medical research company’s stock. Cowen and Company’s price objective would indicate a potential upside of 1.91% from the company’s previous close.
A has been the topic of several other reports. Morgan Stanley reaffirmed an “overweight” rating on shares of Agilent Technologies in a research note on Tuesday, November 14th. Zacks Investment Research lowered Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 16th. Bank of America Corporation reaffirmed an “equal weight” rating on shares of Agilent Technologies in a research note on Tuesday, August 15th. BidaskClub lowered Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Barclays PLC lifted their price objective on Agilent Technologies from $67.00 to $71.00 and gave the company an “overweight” rating in a research note on Tuesday. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $68.20.
Shares of Agilent Technologies (NYSE:A) traded down $1.22 during trading hours on Wednesday, reaching $68.69. The company’s stock had a trading volume of 3,041,700 shares, compared to its average volume of 1,857,755. The company has a current ratio of 3.30, a quick ratio of 2.76 and a debt-to-equity ratio of 0.37. Agilent Technologies has a 12-month low of $42.92 and a 12-month high of $70.81. The firm has a market cap of $21,720.00, a price-to-earnings ratio of 29.50, a price-to-earnings-growth ratio of 2.76 and a beta of 1.28.
COPYRIGHT VIOLATION WARNING: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/11/23/agilent-technologies-inc-a-given-hold-rating-at-cowen-and-company.html.
In related news, Director Boon Hwee Koh sold 4,500 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $63.63, for a total transaction of $286,335.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Didier Hirsch sold 20,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $64.00, for a total value of $1,280,000.00. Following the sale, the chief financial officer now owns 183,002 shares in the company, valued at $11,712,128. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 107,709 shares of company stock worth $7,195,576.
A number of hedge funds have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC purchased a new stake in Agilent Technologies during the 3rd quarter worth approximately $213,000. Public Employees Retirement System of Ohio increased its holdings in Agilent Technologies by 0.9% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 394,744 shares of the medical research company’s stock worth $25,343,000 after purchasing an additional 3,452 shares during the last quarter. Coastline Trust Co increased its holdings in Agilent Technologies by 20.1% during the 3rd quarter. Coastline Trust Co now owns 10,280 shares of the medical research company’s stock worth $660,000 after purchasing an additional 1,720 shares during the last quarter. Hahn Capital Management LLC increased its holdings in Agilent Technologies by 1.0% during the 3rd quarter. Hahn Capital Management LLC now owns 598,781 shares of the medical research company’s stock worth $38,442,000 after purchasing an additional 5,648 shares during the last quarter. Finally, Americafirst Capital Management LLC purchased a new stake in Agilent Technologies during the 3rd quarter worth approximately $743,000.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.